|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 901 E Street, N.W. |
Address2 | Suite 410 |
City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 400496442-12
|
||||||||
|
6. House ID# 410270000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Allison Cohen, Policy Specialist |
Date | 10/19/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions
and provisions on breast health education, research and clinical trials. (Continued on Addendum)
H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional
Directed Medical Research Programs.
Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research,
cancer screening programs and Congressional directed medical research programs.
S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013,
primarily matters related to funding of cancer research and CDC cancer prevention and control programs.
H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing
notification requirements to mitigate drug shortages.
H.R. 3839, Drug Shortage Prevention Act of 2012.
H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011.
H.R.3102, Breast Density and Mammography Reporting Act of 2011.
H.R.3067, Accelerating the End of Breast Cancer Act of 2011.
H.R.3705, Comprehensive Cancer Care Improvement Act of 2011.
H.R.2746, Cancer Drug Coverage Parity Act of 2011.
H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply
chain.
H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy.
S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying
and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions.
S.2236, Advancing Breakthrough Therapies for Patients Act of 2012.
Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug
shortages, drug approval and patient access.
H.R. 4209, Patients' Access to Treatments Act of 2012.
H.R. 5937, Breast Cancer Patient Education Act of 2012.
H.R. 6157, Patient Centered Quality Care for Life Act of 2012
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Allison |
Cohen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |